MX2021013850A - Anticuerpo contra tigit y uso del mismo. - Google Patents
Anticuerpo contra tigit y uso del mismo.Info
- Publication number
- MX2021013850A MX2021013850A MX2021013850A MX2021013850A MX2021013850A MX 2021013850 A MX2021013850 A MX 2021013850A MX 2021013850 A MX2021013850 A MX 2021013850A MX 2021013850 A MX2021013850 A MX 2021013850A MX 2021013850 A MX2021013850 A MX 2021013850A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- tigit
- antigen
- nucleic acid
- composition
- Prior art date
Links
- 101100369641 Mus musculus Tigit gene Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención refiere a: un anticuerpo contra el inmunorreceptor de células T con dominios Ig y motivo inhibidor basado en tirosina (TIGIT), o un fragmento de unión a antígeno del mismo; un ácido nucleico que lo codifica; un vector que lleva el ácido nucleico; una célula transformada con el vector; un método para producir el anticuerpo o el fragmento de unión a antígeno del mismo; y una composición y una composición para administración combinada, que lo comprenden y son para prevenir o tratar el cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190069931 | 2019-06-13 | ||
PCT/KR2020/006705 WO2020251187A1 (ko) | 2019-06-13 | 2020-05-22 | Tigit에 대한 항체 및 이의 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021013850A true MX2021013850A (es) | 2022-01-07 |
Family
ID=73782175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021013850A MX2021013850A (es) | 2019-06-13 | 2020-05-22 | Anticuerpo contra tigit y uso del mismo. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220162310A1 (es) |
EP (1) | EP3985025A4 (es) |
JP (1) | JP7297095B2 (es) |
KR (1) | KR102332847B1 (es) |
CN (1) | CN113840840A (es) |
AU (1) | AU2020290916A1 (es) |
BR (1) | BR112021022171A2 (es) |
CA (1) | CA3139641A1 (es) |
IL (1) | IL287816A (es) |
MX (1) | MX2021013850A (es) |
WO (1) | WO2020251187A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20220611A (es) | 2020-06-02 | 2023-06-07 | Arcus Biosciences Inc | Anticuerpos anti-tigit |
TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Tigit及cd112r阻斷 |
JP2024519331A (ja) * | 2021-05-10 | 2024-05-10 | メディマブバイオ インコーポレイテッド | 抗tigit抗体およびその用途 |
EP4363449A2 (en) * | 2021-07-02 | 2024-05-08 | Genentech, Inc. | Methods and compositions for treating cancer |
WO2023215719A1 (en) | 2022-05-02 | 2023-11-09 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
WO2023234748A1 (ko) * | 2022-06-03 | 2023-12-07 | 메디맵바이오 주식회사 | 항-tigit 항체 및 이의 용도 |
WO2023239226A1 (ko) * | 2022-06-10 | 2023-12-14 | 메디맵바이오 주식회사 | Tigit에 특이적으로 결합하는 항체 및 인터류킨-15를 포함하는 융합 단백질 및 이의 용도 |
WO2023239228A1 (ko) * | 2022-06-10 | 2023-12-14 | 메디맵바이오 주식회사 | 항-tigit 항체, 인터류킨-15, 및 인터류킨-15 수용체 알파 스시 도메인을 포함하는 융합 단백질 및 이의 용도 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL250583B (en) * | 2014-08-19 | 2022-07-01 | Merck Sharp & Dohme | Anti-tigit antibodies |
MX2017007744A (es) | 2014-12-23 | 2017-09-05 | Bristol Myers Squibb Co | Anticuerpos contra el inmunorreceptor de celulas t con dominios de inmunoglobulina y de porcion inhibidora con base en tirosina del inmumorreceptor (tigit). |
TWI715587B (zh) * | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit結合劑和彼之用途 |
UA124573C2 (uk) | 2015-09-25 | 2021-10-13 | Дженентек, Інк. | Антитіло, яке специфічно зв'язується з tigit людини, та спосіб лікування або сповільнення прогресування раку у суб'єкта |
UA125062C2 (uk) | 2015-10-01 | 2022-01-05 | Потенза Терапеутікс, Інк. | Анти-tigit антигензв'язуючі білки і способи їх застосування |
EP3423089A4 (en) * | 2016-03-04 | 2019-10-23 | JN Biosciences, LLC | ANTI-Tigit ANTIBODY |
BR112019010943A8 (pt) | 2016-11-30 | 2023-02-07 | Oncomed Pharm Inc | Usos de um anticorpo que se liga especificamente ao domínio extracelular de tigit humano para a inibição do crescimento do tumor, composição que compreende o dito anticorpo, polinucleotídeo, vetor e célula |
SG11201907278VA (en) | 2017-02-28 | 2019-09-27 | Seattle Genetics Inc | Anti-tigit antibodies |
FI3618863T3 (fi) * | 2017-05-01 | 2023-09-01 | Agenus Inc | Anti-TIGIT-vasta-aineita ja menetelmiä niiden käyttämiseksi |
AU2018261080A1 (en) | 2017-05-02 | 2019-11-07 | Merck Sharp & Dohme Llc | Stable formulations of anti-TIGIT antibodies alone and in combination with programmed death receptor 1 (PD-1) antibodies and methods of use thereof |
BR112020001499A2 (pt) * | 2017-07-27 | 2020-09-08 | Iteos Therapeutics Sa | anticorpos anti-tigit |
WO2019023504A1 (en) * | 2017-07-27 | 2019-01-31 | Iteos Therapeutics Sa | ANTI-TIGIT ANTIBODIES |
-
2020
- 2020-05-22 CA CA3139641A patent/CA3139641A1/en active Pending
- 2020-05-22 EP EP20821874.3A patent/EP3985025A4/en active Pending
- 2020-05-22 MX MX2021013850A patent/MX2021013850A/es unknown
- 2020-05-22 WO PCT/KR2020/006705 patent/WO2020251187A1/ko active Application Filing
- 2020-05-22 US US17/602,511 patent/US20220162310A1/en active Pending
- 2020-05-22 KR KR1020200061409A patent/KR102332847B1/ko active IP Right Grant
- 2020-05-22 CN CN202080036826.7A patent/CN113840840A/zh active Pending
- 2020-05-22 BR BR112021022171A patent/BR112021022171A2/pt unknown
- 2020-05-22 JP JP2021564195A patent/JP7297095B2/ja active Active
- 2020-05-22 AU AU2020290916A patent/AU2020290916A1/en active Pending
-
2021
- 2021-11-03 IL IL287816A patent/IL287816A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3985025A4 (en) | 2023-09-13 |
JP2022536026A (ja) | 2022-08-12 |
CN113840840A (zh) | 2021-12-24 |
KR20200143250A (ko) | 2020-12-23 |
JP7297095B2 (ja) | 2023-06-23 |
EP3985025A1 (en) | 2022-04-20 |
IL287816A (en) | 2022-01-01 |
AU2020290916A1 (en) | 2021-11-04 |
WO2020251187A1 (ko) | 2020-12-17 |
KR102332847B1 (ko) | 2021-12-01 |
CA3139641A1 (en) | 2020-12-17 |
US20220162310A1 (en) | 2022-05-26 |
BR112021022171A2 (pt) | 2021-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021013850A (es) | Anticuerpo contra tigit y uso del mismo. | |
EP4286415A3 (en) | Humanized antigen-binding domains against cd19 and methods of use | |
MX2021007320A (es) | Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor. | |
PH12019501973A1 (en) | Anti-phf-tau antibodies and uses thereof | |
PH12020552010A1 (en) | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof | |
TN2019000272A1 (en) | Anti-ilt4 antibodies and antigen-binding fragments. | |
MX2019003350A (es) | .anticuerpos trivalentes biespecificos unidos a claudina 6 o claudina 18.2 y cd3 para el tratamiento de enfermedades de cancer que expresan claudina. | |
MX2021005008A (es) | Moduladores de celulas t reguladoras multivalentes. | |
MY187971A (en) | Antibody constructs for cd70 and cd3 | |
EA201890302A1 (ru) | Химерные рецепторы антигенов на основе однодоменных антител и способы их применения | |
JO3788B1 (ar) | تراكيب جسم مضاد لـ egfrviii وcd3 | |
TN2017000552A1 (en) | Antibody constructs for msln and cd3. | |
MX2021004588A (es) | Anticuerpo anti-cldn18.2 y sus usos. | |
JOP20190002A1 (ar) | أجسام مضادة (أنتي – بي دي – 1) وطريقة الإنتاج وطريقة استخدام كل منهم | |
EP4242236A3 (en) | Monoclonal antibodies against claudin-18 for treatment of cancer | |
SG10201909308XA (en) | Bispecific antibody constructs for cdh3 and cd3 | |
MX2021007572A (es) | Anticuerpo anti-pd-1 humanizado y uso del mismo. | |
UA100377C2 (en) | Antibodies against il-25 | |
PH12021550244A1 (en) | Anti-btla antibody | |
AU2019433019A8 (en) | Antibodies binding CD40 and uses thereof | |
SA519401032B1 (ar) | (pd-1) جسم مضاد لموت الخلية المبرمج1 واستخدامه | |
ZA202206993B (en) | Anti-lilrb1 antibody and uses thereof | |
MX2021010301A (es) | Composiciones y métodos para el tratamiento de laminopatías. | |
MX2021005323A (es) | Metodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn. | |
CR20220505A (es) | Anticuerpos anti-phf-tau y usos de estos |